Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jun 10;5(6):e003323. doi: 10.1161/JAHA.116.003323

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Hysteresis plots comparing changes over time in LDL‐C vs alirocumab (A) and vs free PCSK9 (B), free PCSK9 vs alirocumab (C), total PCSK9 vs alirocumab (D) and LDL‐C vs total PCSK9 (E). Study variables are plotted on x and y axes with data points representing sample time points (day 0–28 following administration of alirocumab). In the key in (A) “PKD12910” refers to the current study; (A) also includes data from alirocumab Phase I study 1001 for comparison. D indicates study day relative to administration of alirocumab; LDL‐C, low‐density lipoprotein cholesterol; non‐FH, non‐familial hypercholesterolemia; PCSK9, proprotein convertase subtilisin/kexin 9; Q4W, every 4 weeks; SC, subcutaneous.